Pharmaceuticals company Shilpa Medicare announced Q1FY26 results Total Revenue: Rs 328 crore compared to Rs 302 crore during Q1FY25, change 9%. EBITDA: Rs 98 crore compared to Rs 83 crore during Q1FY25, change 18%. EBITDA Margin: 30% for Q1FY26. PAT: Rs 47 crore compared to Rs 14 crore during Q1FY25, change 236%. PAT Margin: 14% for Q1FY26. Vishnukant Bhutada, Managing Director, said: The first quarter of FY26 demonstrated steady progress and strong execution of our strategic priorities. Our partner successfully launched our second NDA in the US, Bortezomib RTU, reinforcing our R&D-driven; approach and delivering differentiated products that enhance ease of administration. Pemetrexed also gained momentum in the U.S., while Nilotinib continued to expand its presence in the EU. Additionally, we achieved a historic milestone with NorUDCA’s approval, making Shilpa the first global company approved for NAFLD treatment. These approvals, along with our robust NDA pipeline, position us for sustained future growth. Our API division(including captive) has reported growth of ~25% YoY basis. New product launches, CDMO expansion, expanded capacities, and an improved product mix favouring regulated markets are expected to drive further growth for FY26. In Biologics, our strategic investment in Alveolus Bio accelerates innovation and solidifies Shilpa’s position as a global biotech enabler, bridging cutting-edge science with scalable solutions. Our Novel Biological Entities (NBEs), developed in collaboration with mAbTree and Alveolus, remain on track for Phase I human trials in FY27. On the biosimilar front, Aflibercept has advanced to Phase III clinical trials in India, while Nivolumab has completed PCT, with Phase I trials expected to commence by the end of FY26. We have also received the initial milestone payment for Recombinant Human Albumin from Orion Corporation, and the program is progressing as planned. On the regulatory front, we continue to achieve key accreditations for our facilities. During the quarter, Unit VI at Dabaspet, Karnataka, equipped with ODF & TDP manufacturing capabilities, received an EIR from the US FDA. This milestone will support the monetisation of our differentiated product portfolio in the US market. Our focus remains on optimising asset utilisation across key verticals, and we are confident in delivering improved profitability in FY26". Result PDF
Conference Call with Shilpa Medicare Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.